This phase III study ( N@ ; NCT@ ) evaluated the efficacy and safety/tolerability of BRV ( @ , @ , and @ mg/day ) compared with placebo ( PBO ) in patients aged @-@ years with uncontrolled focal seizures with/without secondary generalization , despite treatment with one to two concomitant antiepileptic drugs at a stable and optimal dosage .